Visionblue

Vitrectomy therapy, Cataract Surgery

Treatment

2 FDA approvals

3 Active Studies for Visionblue

What is Visionblue

Trypan blue free acid

The Generic name of this drug

Treatment Summary

Trypan blue is a dye used during cataract surgery to make it easier to see the part of the eye that needs to be operated on. It is used when a mature cataract is present and helps doctors create the right incision before removing the cataract.

Visionblue

is the brand name

Visionblue Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Visionblue

Trypan blue free acid

2004

2

Approved as Treatment by the FDA

Trypan blue free acid, commonly known as Visionblue, is approved by the FDA for 2 uses which include Cataract Surgery and Vitrectomy therapy .

Cataract Surgery

Used in combination with other therapies

Vitrectomy therapy

Used in combination with other therapies

Effectiveness

How Visionblue works in the body

Trypan blue ophthalmic drops are a dye used in eye surgery to make certain membranes in the eye easier to see. These membranes include epiretinal membranes (ERM) and Internal Limiting Membranes (ILM).

When to interrupt dosage

The advised measure of Visionblue is contingent upon the determined condition, including Vitrectomy therapy, Cataract Surgery and Therapeutic procedure. The extent of dosage is contingent upon the method of delivery (e.g. Injection, solution - Intraocular; Ophthalmic or Intraocular; Ophthalmic) outlined in the table beneath.

Condition

Dosage

Administration

Vitrectomy therapy

0.06 %, , 3.0 mg/mL, 7.5 mg/mL

Solution / drops - Intraocular, , Intraocular, Solution / drops, Intraocular; Ophthalmic, Injection, solution - Intraocular; Ophthalmic, Injection, solution

Cataract Surgery

0.06 %, , 3.0 mg/mL, 7.5 mg/mL

Solution / drops - Intraocular, , Intraocular, Solution / drops, Intraocular; Ophthalmic, Injection, solution - Intraocular; Ophthalmic, Injection, solution

Warnings

Visionblue Contraindications

Condition

Risk Level

Notes

non-hydrated hydrophilic acrylic lens

Do Not Combine

Common Visionblue Drug Interactions

Drug Name

Risk Level

Description

Visionblue Toxicity & Overdose Risk

The toxic dose of this drug for a rat is 6200 mg/kg when taken orally.

Visionblue Novel Uses: Which Conditions Have a Clinical Trial Featuring Visionblue?

Two current trials are assessing the potential of Visionblue in providing Vitrectomy therapy, Therapeutic procedures and aid in Cataract Surgery.

Condition

Clinical Trials

Trial Phases

Cataract Surgery

3 Actively Recruiting

Not Applicable, Phase 4

Vitrectomy therapy

0 Actively Recruiting

Patient Q&A Section about visionblue

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What do cataracts do?

"A cataract is when the lens in your eye becomes cloudy, which makes it harder to see. Cataracts usually develop in both eyes, but not always at the same time."

Answered by AI

What is vision blue used for?

"VisionBlue is a prescription medication that is used to help during eye surgery by staining the anterior lens capsule. It can be used alone or with other medications and belongs to a class of drugs known as ophthalmic diagnostic agents."

Answered by AI

Why do we get cataracts?

"Many cataracts are caused by typical changes that occur in your eyes as you age. When you are young, the lens in your eye is clear. However, around age 40, the proteins in the lens of your eye start to break down and clump together. This clump forms a cloudy area on your lens, otherwise known as a cataract."

Answered by AI

Why is vision blue used in cataract surgery?

"A cataract is a clouding of the eye's lens that affects vision. Cataracts are usually part of the natural aging process.Most cataracts develop slowly and don't disturb vision early on. Symptoms of cataracts include faded colors, glare, poor night vision, double vision in a single eye, and eventually, a loss of central vision in the affected eye. A cataract can occur in either or both eyes and can lead to blindness.

Cataract surgery is the only way to remove a cataract. The surgeon makes a tiny incision in the eye and inserts an instrument to break up the cataract. Then, the surgeon vacuum suction's out the tiny pieces of the cataract. In most cases, cataract surgery is successful and vision is corrected."

Answered by AI

Clinical Trials for Visionblue

Image of Byers Eye Institute in Palo Alto, United States.

LLM-Based Education for Cataract Surgery

18+
All Sexes
Palo Alto, CA

Patients with cataracts disease need to choose what type of artificial lens will go into their eye prior to surgery date. Some lenses are standard and are usually covered by insurance. Other "premium" lenses have various benefits such as reducing the need for glasses but usually require out-of-pocket costs. The combined busy outpatient clinic and complexity of artificial lens choices in the ever-changing world of cataract surgery tends to lead patients confused about their available lens options. There is an abundance of educational material present in premium lenses, however these are limited by accessibility and are standardized at single educational levels. Therefore in the present study, we want to test whether giving patients a short LLM powered AI-guided explanation from Custom GPT from OpenAI of lens options prior to their consultation with their doctor can improve visit efficiency, physician explanation and patient understanding of lens options. We will compare two groups: standard of care versus standard of care plus AI education. The LLM in this study is intended to provide supplemental information about premium intraocular lens(IOLs) options to study participants, and is no means supposed to replace a health care professional in the diagnosis, cure, treatment, and/or mitigation of disease. Study is analogous to giving a verified health pamphlet to a patient for them to view and learn different IOL options, in other words, facilitating patient understanding of their options. The LLM will be trained by several health care professionals and MD specialists to provide sufficient instructions. Sources will include verified online resources and MD information. The investigators hope to learn if a large language model-based educational tool can improve visit efficiency, physician explanation and patient understanding of intraocular lens options. New knowledge of this study could guide how cataract counseling is delivered in the future and may help clinics spend more time on individualized questions instead of repeating generic information.

Waitlist Available
Has No Placebo

Byers Eye Institute

Robert T Chang, MD

Image of University of California, San Francisco in San Francisco, United States.

Vision Centers for Eye Care

Any Age
All Sexes
San Francisco, CA

The goal of this clinical trial is to evaluate the effect of vision centers on access to eye care and eye health outcomes in South Asia. The main questions it aims to answer are: 1. Do vision centers increase visits to eyecare centers? 2. Do vision centers increase spectacle ownership and wearing? 3. Do vision centers improve visual acuity of the population? Researchers will compare outcomes in communities randomized to have a vision center is established with communities randomized to delay establishment of a vision center. Outcomes will be assessed through population-based surveys at baseline and after two years as well as through hospital records collected throughout the study period.

Waitlist Available
Has No Placebo

University of California, San Francisco

Kieran O'Brien, PhD, MPH